Stocktoria
ARDELYX, INC. ARDX
ARDELYX, INC. (ARDX) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $407.3M at a -15.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.4 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.586 |
| Retained earnings / assets | -1.888 |
| EBIT / assets | -0.082 |
| Equity / liabilities | 0.499 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ARDX | ARDELYX, INC. | 2/9 | -2.34 | — | +22.1% |
| INVA | Innoviva, Inc. | 3/9 | 6.59 | — | +14.7% |
| ESPR | Esperion Therapeutics, Inc. | 3/9 | -8.63 | — | +21.3% |
| SVA | SINOVAC BIOTECH LTD | 3/9 | 8.06 | — | +6.8% |
| ARQT | Arcutis Biotherapeutics, Inc. | 4/9 | -3.68 | — | +91.3% |
| ZLAB | Zai Lab Ltd | 3/9 | -3.61 | — | +15.3% |
| MNKD | MANNKIND CORP | 3/9 | -11.89 | 218.2 | +22.2% |
About ARDELYX, INC.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
FAQ
Is ARDX financially healthy?
ARDELYX, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ARDX pay a dividend?
No, ARDELYX, INC. does not currently pay a dividend.
How profitable is ARDX?
In FY2025, ARDELYX, INC. had a net margin of -15.1% and a return on equity of -36.9%.
What is the analyst price target for ARDX?
The average Wall-Street price target for ARDELYX, INC. is $16.30, about 310.6% above the recent price, from 10 analysts (consensus: strong buy).
Is ARDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ARDELYX, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.